leisure time -WSS

leisure time

author：Wikipedia 2025-09-07 17:23:30 - browse：36961

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Teacher posts viral 'school supply rant' with advice for parents

WSS

Poland's lawmakers approve a divisive law on Russian influence

Many immigrants are left out of maternal health programs

ASCO: Palliative care found as helpful given virtually as in person

At ASCO, AstraZeneca reports strong data for breast cancer drug

How to increase colonoscopy rates? Looks like an AI can help

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

New air purifier tech could be key to improving indoor air quality

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Virginia high school admissions case could be legal follow

What AstraZeneca

United colonoscopy coverage change 'may cost lives,' doctors say

Ultragenyx gene therapy for rare liver ailment succeeds in late

Cancer drug shortages should be causing more outrage

FDA's Pazdur wants cancer trials to range beyond China alone

knowledge

Cord blood banking comes at a high cost to babies

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Let's speed up science by embracing open access publishing

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

hotspot

entertainment

knowledge

leisure time